Today 50% of new treatments fail due to non drug efficacy-related reasons. 86% of clinical trial sites do not meet enrollment goals.
For clinical trials that do complete, there is a high degree of post-market failures due to relevance and applicability in real-world settings.
MACRO is a new type of clinical research platform, purpose-built to execute on tomorrow's landscape of clinical trials.
We take a human approach to accelerating life-saving treatments, with patients at our core and an agile, outcomes-focused model.
Get more information about becoming a Macro sponsor by filling out the below form. Your responses will remain confidential.
exceeded in completed studies conducted by Macro
when compared to leading academic medical centers
rates for those who start their trial journey with Macro
Phase IB, II, III, IV and post market study experience
Our turnkey, plug and play infrastructure is built for efficiency across in-person, virtual, and hybrid trials. Macro's certified, full-time clinical research team operates across Macro's remote platform and state-of-the-art clinical facilities.
Our high-touch model leverages our deep understanding of patient needs, cultural competence and focuses on each engagement with the patient.
Our combined 40 years of industry experience and high-quality national network of logistics partners allows Macro to comply with evolving regulatory and compliance changes.
Macro’s data analytics strategy helps optimize protocol design and patient selection across a sponsor’s drug development program.
Macro Trials – a new precision research clinical platform – recently launched to transform clinical trials. And the company’s founders incubated Macro Trials with INITIATE Studios, a venture studio that co-creates companies at the intersection of healthcare, life sciences, and technology.
Read MoreIn time for Rare Disease Day, orphan-disease patients, site managers and service providers discuss challenges obstacles faced in trial participation.
Read MoreMACRO Trials (MACRO) is shifting the paradigm for performing clinical trials through a progressive, streamlined model that has emerged particularly steadfast during the COVID-19 crisis.
Read More